Q1 2025 Mediwound Ltd Earnings Call Transcript
Key Points
- MediWound Ltd (MDWD) is making strong progress with the VALUE Phase 3 trial of EscharEx, which is on track and strategically derisked.
- The company has secured a EUR2.5 million grant from the European Innovation Council Accelerator to support EscharEx's clinical and regulatory advancement.
- NexoBrid is experiencing significant global traction, with a 207% year-over-year increase in US revenue and high demand in Japan and Europe.
- MediWound Ltd (MDWD) is expanding its manufacturing capabilities with a new facility expected to be operational by the end of 2025, supporting long-term growth.
- The company has strong strategic alliances with major wound care companies, enhancing its clinical development programs and market positioning.
- Total revenue for the first quarter of 2025 decreased to $4 million from $5 million in the same period in 2024, reflecting lower BARDA-funded development services revenue.
- Operating loss increased to $5.2 million from $3.7 million in Q1 2024, driven by higher R&D expenses.
- The company used $5.1 million to fund operations during the quarter, reducing cash reserves from $43.6 million at year-end 2024 to $38.7 million.
- There is uncertainty regarding the timing of FDA inspections for the new manufacturing facility, which could impact future production timelines.
- The potential EUR13.75 million equity investment from the European Innovation Council Accelerator may not materialize, which could affect funding for future projects.
Good day, and welcome to the MediWound first-quarter 2025 earnings call.(Operator instructions) Please note this event is being recorded.
I would now like to turn the conference over to Dan Ferry of LifeSci Advisors. Please go ahead.
Thank you, operator, and welcome, everyone. Earlier today, pre-market opened, MediWound issued a press release announcing financial results for the first quarter ended March 31, 2025. You may access this press release on the company's website under the Investors tab.
I would ask you to review the full text of our forward-looking statements within this morning's press release. Before we begin, I would like to remind everyone that statements made during this call, including in the Q&A session, relating to MediWound's expected future performance, future business prospects or future events or plans are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995.
These statements may involve risks and uncertainties that could
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
